S. Abbas, S. Lugthart, F. G. Kavelaars, A. Schelen, J. E. Koenders et al., Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value, Blood, vol.116, pp.2122-2126, 2010.

L. Altucci, A. Rossin, O. Hirsch, A. Nebbioso, D. Vitoux et al., Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor, Cancer Res, vol.65, pp.8754-8765, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00187351

F. O. Bagger, N. Rapin, K. Theilgaard-mönch, B. Kaczkowski, L. A. Thoren et al., HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis, Nucleic Acids Res, vol.41, issue.D1, pp.1034-1039, 2013.

A. K. Burnett, R. K. Hills, C. Green, S. Jenkinson, K. Koo et al., The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEB PA, Blood, vol.115, pp.948-956, 2010.

S. M. Chan, D. Thomas, M. R. Corces-zimmerman, S. Xavy, S. Rastogi et al., Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia, Nat. Med, vol.21, pp.178-184, 2015.

M. K. Chelbi-alix and L. Pelicano, Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells, Leukemia, vol.13, pp.1167-1174, 1999.

A. P. Chou, R. Chowdhury, S. Li, W. Chen, A. J. Kim et al., Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas, J. Natl. Cancer Inst, vol.104, pp.1458-1469, 2012.

L. Dang, D. W. White, S. Gross, B. D. Bennett, M. A. Bittinger et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, vol.462, pp.739-744, 2009.

C. D. Dinardo, K. J. Propert, A. W. Loren, E. Paietta, Z. Sun et al., Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia, Blood, vol.121, pp.4917-4924, 2013.

D. Santos, C. , C. Demur, V. Bardet, N. Prade-houdellier et al., A critical role for Lyn in acute myeloid leukemia, Blood, vol.111, pp.2269-2279, 2008.

A. T. Fathi, H. Sadrzadeh, A. H. Comander, M. J. Higgins, A. Bardia et al., Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate, Oncologist, vol.19, pp.602-607, 2014.

G. Ferrari-amorotti, K. Keeshan, M. Zattoni, C. Guerzoni, G. Iotti et al., Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBP?, Blood, vol.108, pp.1353-1362, 2006.

M. E. Figueroa, O. Abdel-wahab, C. Lu, P. S. Ward, J. Patel et al., Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, Cancer Cell, vol.18, pp.553-567, 2010.

M. E. Figueroa, S. Lugthart, Y. Li, C. Erpelinck-verschueren, X. Deng et al., DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia, Cancer Cell, vol.17, pp.13-27, 2010.

C. L. Green, C. M. Evans, L. Zhao, R. K. Hills, A. K. Burnett et al., The prognostic significance of IDH2 mutations in AML depends on the location of the mutation, Blood, vol.118, pp.409-412, 2011.

P. Guilhamon, M. Eskandarpour, D. Halai, G. A. Wilson, A. Feber et al., Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2, Nat. Commun, vol.4, p.2166, 2013.

M. S. Hasemann, F. K. Lauridsen, J. Waage, J. S. Jakobsen, A. K. Frank et al.,

. Porse, C/EBP? is required for long-term self-renewal and lineage priming of hematopoietic stem cells and for the maintenance of epigenetic configurations in multipotent progenitors, PLoS Genet, vol.10, p.1004079, 2014.

M. Janin, E. Mylonas, V. Saada, J. B. Micol, A. Renneville et al., Serum 2-hydroxyglutarate production in IDH1-and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group, J. Clin. Oncol, vol.32, pp.297-305, 2014.

L. M. Kats, M. Reschke, R. Taulli, O. Pozdnyakova, K. Burgess et al., Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance, Cell Stem Cell, vol.14, pp.329-341, 2014.

A. Kernytsky, F. Wang, E. Hansen, S. Schalm, K. Straley et al., IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by smallmolecule inhibition, Blood, vol.125, pp.296-303, 2015.

C. V. Laiosa, M. Stadtfeld, and T. Graf, Determinants of lymphoidmyeloid lineage diversification, Annu. Rev. Immunol, vol.24, pp.705-738, 2006.

J. A. Losman, R. E. Looper, P. Koivunen, S. Lee, R. K. Schneider et al., (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible, Science, vol.339, pp.1621-1625, 2013.

C. Lu, P. S. Ward, G. S. Kapoor, D. Rohle, S. Turcan et al., IDH mutation impairs histone demethylation and results in a block to cell differentiation, Nature, vol.483, pp.474-478, 2012.

E. R. Mardis, L. Ding, D. J. Dooling, D. E. Larson, M. D. Mclellan et al., Recurring mutations found by sequencing an acute myeloid leukemia genome, N. Engl. J. Med, vol.361, pp.1058-1066, 2009.

Y. Matsuo, R. A. Macleod, C. C. Uphoff, H. G. Drexler, C. Nishizaki et al., Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23), Leukemia, vol.11, pp.1469-1477, 1997.

A. Nazha, C. Bueso-ramos, E. Estey, S. Faderl, S. O'brien et al., The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia, Front. Oncol, vol.3, p.218, 2013.

H. S. Radomska, C. S. Huettner, P. Zhang, T. Cheng, D. T. Scadden et al., CCA AT/enhancer binding protein ? is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors, Mol. Cell. Biol, vol.18, pp.4301-4314, 1998.

A. Sakashita, T. Nakamaki, N. Tsuruoka, Y. Honma, and M. Hozumi, Granulocyte colony-stimulating factor, not granulocyte-macrophage colony-stimulating factor, co-operates with retinoic acid on the induction of functional N-formyl-methionyl-phenylalanine receptors in HL-60 cells, Leukemia, vol.5, pp.26-31, 1991.

M. Sasaki, C. B. Knobbe, J. C. Munger, E. F. Lind, D. Brenner et al., IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics, Nature, vol.488, pp.656-659, 2012.

H. Schepers, A. T. Wierenga, D. Van-gosliga, B. J. Eggen, E. Vellenga et al., Reintroduction of C/EBP? in leukemic CD34 + stem/ progenitor cells impairs self-renewal and partially restores myelopoiesis, Blood, vol.110, pp.1317-1325, 2007.

R. F. Schlenk, K. Döhner, M. Kneba, K. Götze, F. Hartmann et al., German-Austrian AML Study Group (AML SG). 2009. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia, Results from the AML SG Trial AML HD98B

, Haematologica, vol.94, pp.54-60

M. Shen, R. P. Bunaciu, J. Congleton, H. A. Jensen, L. G. Sayam et al., Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acidinduced differentiation of HL-60 human myelo-monoblastic leukemia cells, Leuk. Lymphoma, vol.52, pp.2372-2379, 2011.

L. I. Shlush, S. Zandi, A. Mitchell, W. C. Chen, J. M. Brandwein et al., Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia, Nature, vol.506, pp.328-333, 2014.

S. Turcan, D. Rohle, A. Goenka, L. A. Walsh, F. Fang et al., IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, Nature, vol.483, pp.479-483, 2012.

R. G. Verhaak, B. J. Wouters, C. A. Erpelinck, S. Abbas, H. B. Beverloo et al., Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling, Haematologica, vol.94, pp.131-134, 2009.

F. Wang, J. Travins, B. Delabarre, V. Penard-lacronique, S. Schalm et al., Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation, Science, vol.340, pp.622-626, 2013.

J. H. Wang, W. L. Chen, J. M. Li, S. F. Wu, T. L. Chen et al., Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China, Proc. Natl. Acad. Sci. USA, vol.110, pp.17017-17022, 2013.